The Importance of Early Recognition of Tay-Sachs and Sandhoff Disease

To participate in this activity, please:

Log in Sign Up

Faculty experts, Jeanine Jarnes, PharmD, and Chester Whitley, MD, PhD delve into the rare and difficult to diagnose GM2-gangliosidoses Tays-Sachs and Sandhoff diseases. Following a discussion of the etiology and pathophysiology of these diseases, the faculty use real-life cases to illustrate the various phenotypes of these conditions, as well as key presenting signs and symptoms. Diagnostic approaches are discussed, alongside current standards of care, including supportive and palliative treatment options. Drs. Jarnes and Whitley describe key therapeutic approaches under investigation to improve outcomes of patients with Tay-Sachs and Sandhoff disease.

This program is also available as a podcast. You may download it here: https://podcasters.spotify.com/pod/show/tay-sachssandhoff

Course Credit:

0.75 AAPA Category I Hours
0.75 AMA PRA Category 1 CreditsTM
0.75 ANCC Contact Hours
0.75 CA-BRN Contact Hours
0.25 Pharmacology Hours

Dates:

Opens: 2023-07-26
Closes: 2024-07-26

Target Audience:

This activity is intended for neurologists, family physicians, internists, geneticists, psychiatrists, psychologists, advanced practice providers, and other clinicians who diagnose or manage patients with GM2 gangliosidoses, specifically Tay-Sachs and Sandhoff disease.

Supported by an independent educational grant from Sanofi.

Accreditation Information

Accreditation

In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Annenberg Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 hours AAPA Category 1 CME credits. Approval is valid until July 26, 2024. PAs should only claim credit commensurate with the extent of their participation.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 contact hours, including 0.25 pharmacology hours.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 0.75 contact hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

Additional Content Planners

Amber Lambert, MSN, FNP-C, DNP (Nurse Planner)
No significant relationships to disclose.

Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.

Sunali Wadehra, MD (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Jeanine Jarnes, PharmD, MSc, BCOP, BCPS

    Assistant Professor, Department of Pediatrics
    University of Minnesota Medical School
    Pharmacotherapy for Inherited Metabolic Diseases
    Advanced Therapies Department
    College of Pharmacy, Experimental and Clinical Pharmacology
    Minneapolis, Minnesota

  • Chester B. Whitley, MD, PhD

    Professor
    Medical Director, Advanced Therapies Program
    Director, Gene Therapy Center
    Director, PKU Clinic Member, Masonic Cancer Center
    Departments of Pediatrics, and
    Experimental and Clinical Pharmacology
    College of Pharmacy
    University of Minnesota
    Minneapolis, Minnesota

Learning Objectives

  • Identify the most common presenting signs and symptoms of GM2 gangliosidoses
  • Differentiate GM2 gangliosidoses from other possible diagnoses
  • Classify emerging treatments for the GM2 gangliosidoses

Faculty Disclosures

Jeanine Jarnes, PharmD, MSc, BCOP, BCPS

Consultant: Lysogene, Passage Bio, Sio


Chester B. Whitley, MD, PhD

No relationships to disclose.